Ovarian Cysts Market Analysis

Global Ovarian Cysts Market Overview

The Ovarian Cysts Market Size was valued at USD 0.5 Billion in 2022. The Ovarian Cysts market industry is projected to grow from USD 0.6 Billion in 2023 to USD 3.3 Billion by 2032, exhibiting a compound annual growth rate (CAGR) of 23.5% during the forecast period (2023 - 2032). 

Further fueling the market's expansion are developments in medical technology and minimally invasive techniques that are making it possible to treat ovarian cysts more safely and effectively are the key market drivers enhancing the market growth. 

Source: Secondary Research, Primary Research, MRFR Database, and Analyst Review

Ovarian Cysts Market Trends

• 
  

  Increasing prevalence of ovarian cysts among women powering the market growth

  
  

Market CAGR will increase due to the occurrence of ovarian cysts due to several variables. Hormonal abnormalities are one important issue. Hormones significantly influence the menstrual cycle and ovarian cysts' growth. Cysts can develop in the ovaries due to hormonal imbalances in estrogen and progesterone that prevent the ovaries from functioning normally. 

In addition, lifestyle choices like obesity and inactivity have been linked to increased ovarian cyst occurrence. Cysts can develop due to hormonal imbalances, insulin resistance, and elevated estrogen levels, all linked to obesity. Sedentary lifestyles, characterized by a lack of exercise, can also affect hormone levels and cause ovarian cysts.

Ovarian cyst prevalence is also influenced by increased knowledge and better diagnostic methods. Women's health has received more attention recently, raising public awareness of gynecological disorders, including ovarian cysts. To identify and track ovarian cysts, women are now more likely to visit a doctor and have diagnostic tests done. Furthermore, improvements in medical imaging technology like magnetic resonance imaging (MRI) and ultrasound have increased the precision and early diagnosis of ovarian cysts. These developments allow medical personnel to identify cysts early, allowing for prompt intervention and treatment. 

The greater occurrence of ovarian cysts is also a result of the aging population. Ovarian cysts are more likely to occur in older women. This is due to hormonal changes during perimenopause and menopause, which can impair regular ovarian function and result in cyst formation. Ovarian cysts are more common overall due to the aging population that is expanding worldwide and women's longer life expectancies. The need for efficient diagnostic and therapeutic alternatives has increased due to the rising occurrence of ovarian cysts. Women with ovarian cysts frequently encounter pelvic pain, bloating, and irregular menstruation cycles are common symptoms. 

These symptoms can negatively influence a woman's quality of life. As a result, the demand for precise and effective diagnostic instruments to determine cysts' presence, size, and features is rising. This includes imaging methods like computed tomography (CT) scans, MRIs, and ultrasounds.

There is also a need for medical procedures that can properly treat ovarian cysts. Treatment options range from surgical operations like cystectomy (removal of the cyst) or oophorectomy (removal of the afflicted ovary) to conservative management methods like careful waiting and hormone medication. The type and size of the cyst, the severity of the symptoms, and the patient's reproductive objectives all play a role in the treatment decision. Thus, driving the Ovarian Cysts market revenue.

Ovarian Cysts Market Segment Insights

Ovarian Cysts Type Insights

The Ovarian Cysts market segmentation is based on type, functional cysts, non-functional cysts, and others. Functional cysts are the most popular product among those connected to the ovarian cysts market. The most frequent kind of ovarian cysts, known as functional cysts, are produced by regular menstrual cycle activities. Usually, these cysts form and disappear on their own after a few menstrual cycles. Functional cysts are the most often used product on the market because of their high prevalence and tendency to resolve independently. This is because they are treated conservatively with hormonal therapy and patient waiting.

Figure 1: Ovarian Cysts Market, by Type, 2022 & 2032 (USD Billion) 

Source: Secondary Research, Primary Research, MRFR Database, and Analyst Review

Ovarian Cysts Diagnosis Insights

The Ovarian Cysts market segmentation is based on diagnosis, imaging, CA-125 blood test, laparoscopy, and others. Imaging is the most popular product among those connected to the ovarian cysts market. Ovarian cysts must be diagnosed and monitored using imaging techniques like ultrasound, magnetic resonance imaging (MRI), and computed tomography (CT) scans. These imaging techniques offer a sweeping view of the ovaries, enabling medical practitioners to precisely identify and evaluate cyst size, location, and features. Imaging is the most popular ovarian cyst treatment available since it is important to determine the best course of action and monitor the effectiveness of therapies.

Ovarian Cysts Treatment Insights

The Ovarian Cysts market segmentation is based on treatments, including medication, polycystic ovary syndrome (PCOS) drugs, pain relievers, surgery, and others. Medicine is the most popular product among those connected to the ovarian cysts market. Depending on the kind, size, and symptoms of the cysts, medications are frequently administered to treat ovarian cysts. To control hormone levels and stop the growth of new cysts, hormone therapies such as birth control tablets or hormone-releasing intrauterine devices (IUDs) are frequently utilized. Specific medications that address insulin resistance and hormonal abnormalities may be recommended in PCOS situations. Ovarian cyst management with medication is popular since it offers a non-invasive therapeutic option.

Latest Industry Developments in Ovarian Cysts Treatment Segment

June 2024: Merck has released a combination therapy for ovarian cyst pain, combining a pain reliever and anti-inflammatory drug, which has been proven to be more effective in managing pain and reducing inflammation compared to traditional methods.

May 2024: Pfizer has introduced a new drug for managing Polycystic Ovary Syndrome (PCOS), targeting insulin resistance. The medication improves menstrual cycles, reduces ovarian cysts, manages weight, and reduces androgen levels, thereby enhancing overall PCOS management.

April 2024: Boston Scientific has launched a minimally invasive surgical device for ovarian cyst removal, utilizing advanced laparoscopic technology and real-time imaging to improve precision, reduce recovery time, and enhance surgical outcomes.

 Ovarian Cysts End User Insights

The Ovarian Cysts market segmentation is based on tests, including hospitals & clinics, medical institutes, research organizations, and others. Hospitals and clinics are the most commonly utilized product among those connected to the ovarian cysts market. When it comes to ovarian cyst diagnosis, management, and treatment, hospitals and clinics are indispensable. They act as the main healthcare facilities where patients receive medical care, conduct diagnostic procedures, including imaging and blood testing, get advice from medical experts, and, if required, have surgery. To meet the needs of patients in the market, hospitals and clinics offer a variety of medical treatments and expertise to women with ovarian cysts.

Ovarian Cysts Regional Insights

By region, the study provides market insights into North America, Europe, Asia-Pacific, and the Rest of the World. Among those mentioned, North America is the region most frequently connected with the ovarian cysts market. The healthcare system in North America is well-established, there are cutting-edge medical technologies, and there is a high degree of knowledge of and accessibility to healthcare services. Women's health is the subject of many research and development projects. Ovarian cyst prevalence is also rather high in North America, which adds to the market's popularity there.

Further, the major countries studied in the market report are The US, Canada, German, France, the UK, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil.

Figure 2: Ovarian Cysts Market Share By Region 2022 (USD Billion)

Source: Secondary Research, Primary Research, MRFR Database, and Analyst Review

Europe Ovarian Cysts market accounts for the second-largest market share. The Ovarian Cysts Market is most commonly accepted in Europe. This can be attributed to its sophisticated healthcare infrastructure, high awareness levels, accessibility to healthcare services, and extensive research and development efforts. Further, the German Ovarian Cysts market held the largest market share, and the UK Ovarian Cysts market was the fastest-growing market in the European region.

The Asia-Pacific Ovarian Cysts Market is expected to grow at the fastest CAGR from 2023 to 2032. Due to its sizable population, rising healthcare costs, increasing awareness of women's health, and rising prevalence of ovarian cysts, the Asia Pacific area is the most widely recognized in the market. Moreover, China’s Ovarian Cysts market held the largest market share, and the Indian Ovarian Cysts market was the fastest-growing market in the Asia-Pacific region.

Ovarian Cysts Key Market Players & Competitive Insights

Leading market players are expected to increase their footprint by investing heavily in manufacturing units during the forecast periods. Market participants are also undertaking various strategic activities to expand their footprint, with important market developments including new Type launches, contractual agreements, mergers and acquisitions, higher investments, and collaboration with other organizations. The market leaders for the Ovarian Cysts industry are expected to increase their revenue by increasing sales.

The prominent manufacturers of the Ovarian Cysts industry are increasing their footprint by investing heavily in increasing their volumetric capacities. During the forecast period, the Ovarian Cysts industry will make incredible changes in their outcomes. Major Ovarian Cysts market players include Pfizer Inc., Teva Pharmaceutical Industries Ltd, Quest Diagnostics Incorporated, and Novartis AG, which is attempting to increase market demand by investing in research and development operations.

Leading pharmaceutical corporation Pfizer Inc. has its headquarters in New York City, in the United States. Pfizer, founded in 1849, has grown to be one of the biggest and most reputable companies in the pharmaceutical sector. Pfizer develops, produces, and markets cutting-edge prescription medications, vaccines, and consumer healthcare products. Pfizer has a long history of almost 170 years and is dedicated to enhancing health outcomes. The organization works in various therapeutic fields, such as neuroscience, cardiology, oncology, immunology, rare disorders, and vaccines. The varied portfolio of Pfizer includes patented and generic medicines, meeting the demands of a wide range of patients. Pfizer's accomplishments result from its commitment to research and development (R&D). 

The business makes significant investments in scientific research. It has a wide range of investigational pharmaceuticals in various stages of development. Collaboration with academic institutions, governmental agencies, and other industry partners drives Pfizer's R&D initiatives, allowing the business to remain a leader in medical innovation. An international pharmaceutical corporation with its main office in Petah Tikva, Israel, is Teva Pharmaceutical Industries Ltd. 

Teva was founded in 1901 and has grown to become one of the biggest generic pharmaceutical producers in the world as well as a significant force in specialty drugs and active pharmaceutical ingredients (APIs). The goal of Teva is to increase access to high-quality, affordable medicines and to improve health. The company's extensive product portfolio covers a wide range of therapeutic areas, such as diseases of the central nervous system, respiratory issues, oncology, pain management, and more. 

The vast line of generic medications available from Teva provides patients, healthcare professionals, and healthcare systems worldwide with affordable alternatives to name-brand drugs. Teva is renowned for its dedication to innovation and makes considerable investments in R&D. The business runs several R&D facilities worldwide and employs a gifted group of scientists and researchers dedicated to developing new treatments and refining current drug formulations. In addition to creating generic drugs, Teva also creates specialty medications and biosimilars to meet unmet medical needs.

Key Companies in the Ovarian Cysts market include

• Pfizer Inc.


• Teva Pharmaceutical Industries Ltd


• Quest Diagnostics Incorporated


• Novartis AG


• General Electric Company


• Merck & Co., Inc


• Boston Scientific Corporation


• Medtronic

Ovarian Cysts Industry Developments

May 2021: AstraZeneca reported encouraging findings from a Phase III study examining the effectiveness and safety of their investigational medicine, selumetinib, in patients with recurrent or resistant plexiform neurofibromas (PNs) linked with neurofibromatosis type 1 (NF1) in May 2021. In NF1 patients, these PNs are frequently accompanied by ovarian cysts. The study showed significant tumor volume reductions, revealing a possible therapy for cyst-associated problems in NF1.

February 2021: Ethicon, a division of Johnson & Johnson, got FDA approval for its novel energy device known as ENSEAL® X1 Large Jaw Tissue Sealer in February 2021. This gadget can secure vascular closure and enhance energy control during laparoscopic surgery, including operations for ovarian cysts, giving surgeons greater accuracy and productivity.

Ovarian Cysts Market Segmentation

Ovarian Cysts Type Outlook

•  Functional Cysts


• Non-Functional Cysts


• Others

Ovarian Cysts Diagnosis Outlook

• Imaging


• CA-125 Blood Test


• Laparoscopy


• Others

Ovarian Cysts Treatment Outlook

• Medication


• Polycystic Ovary Syndrome (PCOS) Drugs


• Pain Relievers


• Surgery


• Others

Ovarian Cysts End User Outlook

• Hospitals & Clinics


• Medical Institutes


• Research Organization


• Others

Ovarian Cysts Regional Outlook

• North America
  
  
  
  • US
  
  
  • Canada
  
  
  
  


• Europe
  
  
  
  • Germany
  
  
  • France
  
  
  • UK
  
  
  • Italy
  
  
  • Spain
  
  
  • Rest of Europe
  
  
  
  


• Asia-Pacific
  
  
  
  • China
  
  
  • Japan
  
  
  • India
  
  
  • Australia
  
  
  • South Korea
  
  
  • Australia
  
  
  • Rest of Asia-Pacific
  
  
  
  


• Rest of the World
  
  
  
  • Middle East
  
  
  • Africa
  
  
  • Latin America